Alligator Bioscience AB (FRA:7AL0) FCF Yield %: -102.01 (As of Jun. 30, 2026)


FRA:7AL0 Alligator Bioscience AB FRA:7AL0
39 GF Score
Price €0.00
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB FCF Yield %?

Alligator Bioscience AB FRA:7AL0 39 FCF Yield % is -102.01 as of Jun. 30, 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 1,415 Biotechnology companies, Alligator Bioscience AB ranks worse than 90.88% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Alligator Bioscience AB's Trailing 12-Month Free Cash Flow is €-10.39 Mil, and Market Cap is €10.02 Mil. Therefore, Alligator Bioscience AB's FCF Yield % for today is -102.01%.

The historical rank and industry rank for Alligator Bioscience AB's FCF Yield % or its related term are showing as below:

FRA:7AL0' s FCF Yield % Range Over the Past 10 Years
Min: -250094.35   Med: -33.89   Max: -1.86
Current: -102.01


During the past 12 years, the highest FCF Yield % of Alligator Bioscience AB was -1.86%. The lowest was -250094.35%. And the median was -33.89%.

FRA:7AL0's FCF Yield % is ranked worse than
90.88% of 1415 companies
in the Biotechnology industry
Industry Median: -9.49 vs FRA:7AL0: -102.01

Alligator Bioscience AB's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Alligator Bioscience AB FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Alligator Bioscience AB FCF Yield % Related Terms


Alligator Bioscience AB FCF Yield % Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB FCF Yield % Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.38 -40.22 -36.51 -124.25 -132.23

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -175.53 -22.48 -61.59 -92.20 -22,849.61

FRA:7AL0 vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's FCF Yield % falls into.


FRA:7AL0
39GF Score
Alligator Bioscience AB FRA:7AL0
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Alligator Bioscience AB's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-14.468 / 10.941634
=-132.23%

Alligator Bioscience AB's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.588 * 4 / 0.0628107
=-22,849.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -102.01 mean?
Alligator Bioscience AB (FRA:7AL0) has a FCF Yield % of -102.01 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #1286 out of 1415 companies in the Biotechnology industry, placing it in the top 90.9%.
Is Alligator Bioscience AB's FCF Yield % too high?
Alligator Bioscience AB's current FCF Yield % is -102.01. Based on the distribution chart, Alligator Bioscience AB ranks #1286 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alligator Bioscience AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #1286 out of 1415 companies for FCF Yield %. This places Alligator Bioscience AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current FCF Yield % is -102.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current FCF Yield % of -102.01. The current FCF Yield % is -102.01. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current FCF Yield % is -102.01 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for FRA:7AL0

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price